Shots:
- Ginkgo is eligible to receive up front, R& D fees including milestones in the form of Selecta common stock, clinical & commercial milestones of ~$85M in cash along with royalties on sales
- The collaboration will utilize Ginkgo’s cell programming platform & Selecta’s ImmTOR platform to develop transformative enzymatic therapies. The collaboration builds on preclinical/clinical data from Selecta’s P-II COMPARE trial for chronic refractory gout which supports ImmTOR for therapeutic benefit combined with immunogenic enzymatic therapies
- Selecta obtains rights to develop & commercialize therapeutic enzymes from Ginkgo’s engineering platform for auto-immune diseases
Click here to read full press release/ article | Ref: PR Newswire | Image: Selecta Bio
The post Selecta Collaborates with Ginkgo to Develop Therapeutic Enzymes for the Treatment of Orphan and Rare Diseases first appeared on PharmaShots.
